Analyze Diet
Equine veterinary journal2023; doi: 10.1111/evj.14008

Equine allogeneic tenogenic primed mesenchymal stem cells: A clinical field study in horses suffering from naturally occurring superficial digital flexor tendon and suspensory ligament injuries.

Abstract: Mesenchymal stem cells are an innovative therapeutic for various equine orthopaedic diseases, including soft tissue injuries. Objective: To evaluate the safety and efficacy of tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs) in horses with naturally occurring superficial digital flexor tendon (SDFT) and suspensory ligament (SL) injuries. Methods: Multicentre, blinded, randomised, placebo-controlled clinical trial. Methods: One hundred client-owned horses with SDFT and SL injuries were randomised to receive an intralesional tpMSC (66) or saline (34) injection. Clinical and ultrasonographic evaluation was performed before treatment and on Days 56 ± 3 and 112 ± 3 after treatment. Long-term data on re-injury was collected up to 2 years after treatment. Results: Significantly more tpMSC-treated horses achieved improvement in fibre alignment score (FAS) (100% vs. 54.5%, p < 0.001) and echogenicity (97.0% vs. 57.6%, p < 0.001) on Day 112 ± 3, and their lesion size decreased significantly (-27.6 ± 25.91 vs. -4.6 ± 26.64 mm , p < 0.001) compared to the placebo group. A FAS = 0 was achieved in 65% of tpMSC-treated horses, as compared to 9% of placebo-treated horses at Day 112 ± 3. The attending veterinarians reported no re-injury in 41 of 53 tpMSC and in 2 of 26 saline-treated horses available for long-term follow-up (p < 0.001). Conclusions: As this study consisted of client-owned horses, no samples for histology were collected. Long-term follow-up was only available for a subset of enrolled horses. Conclusions: The intralesional administration of tpMSCs was safe and improved the quality of healing and long-term outcomes in sports horses with naturally occurring SDFT and suspensory injuries.
Publication Date: 2023-10-17 PubMed ID: 37847100DOI: 10.1111/evj.14008Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the safety and efficacy of mesenchymal stem cells, which have undergone tenogenic priming, in the treatment of tendon and ligament injuries in horses. The study indicates a significant improvement in the healing and long-term outcomes of horses treated with these stem cells compared to a placebo group.

Research Objective and Methods

  • The primary goal of the research was to assess the safety and effectiveness of tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs) in the treatment of naturally occurring superficial digital flexor tendon (SDFT) and suspensory ligament (SL) injuries in horses. The assessment was done through a randomised, placebo-controlled clinical trial.
  • The study involved 100 horses owned by clients with SDFT and SL injuries, with 66 being treated via tpMSC intralesional injection and the remaining 34 receiving saline injections.
  • Pre-treatment clinical and ultrasonographic evaluations were performed, followed by subsequent assessments on Days 56 ± 3 and 112 ± 3 after treatment, and long-term follow-up data on re-injury was collected for up to two years after treatment.

Study Results

  • The results of the study showed noticeable improvement in tendon and ligament health among the horses treated with tpMSCs as opposed to those in the placebo group. One hundred percent of the tpMSC treated horses achieved improvement in fibre alignment score (FAS), compared to just over half in the placebo group.
  • The lesion sizes also decreased significantly in the tpMSC group as compared to the placebo group. At Day 112 ± 3, 65% of tpMSC-treated horses achieved a FAS of zero, compared to 9% of horses in the placebo group.
  • The veterinarians reported no re-injury in 41 out of 53 tpMSC treated horses in long-term follow-up, while this was only the case for 2 out of 26 horses in the saline-treated placebo group.

Study Limitations and Conclusion

  • The study had its limitations in that no samples for histology were collected since the study comprised client-owned horses. Also, long-term follow-up was only available for some of the enrolled horses.
  • Nonetheless, the study concludes that the intralesional administration of tpMSCs is safe and enhances the quality of healing and long-term outcomes in sports horses with naturally occurring SDFT and suspensory injuries.

Cite This Article

APA
Carlier S, Depuydt E, Suls M, Bocqué C, Thys J, Vandenberghe A, Martens A, Saunders J, Hellmann K, Braun G, Beerts C, Spaas JH. (2023). Equine allogeneic tenogenic primed mesenchymal stem cells: A clinical field study in horses suffering from naturally occurring superficial digital flexor tendon and suspensory ligament injuries. Equine Vet J. https://doi.org/10.1111/evj.14008

Publication

ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Carlier, Stephanie
  • Boehringer Ingelheim Veterinary Medicine Belgium, Evergem, Belgium.
  • Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
  • Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Depuydt, Eva
  • Boehringer Ingelheim Veterinary Medicine Belgium, Evergem, Belgium.
  • Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Suls, Marc
  • Praktijk Dr. Suls BV, Nederweert, the Netherlands.
  • Via Nova Equine, Bree, Belgium.
Bocqué, Cedric
  • Via Nova Equine, Bree, Belgium.
Thys, Justine
  • Via Nova Equine, Bree, Belgium.
Vandenberghe, Aurélie
  • Equine Veterinary Services Adriaensen-Vandenberghe, Evergem, Belgium.
Martens, Ann
  • Department of Large Animal Surgery, Anaesthesia and Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Saunders, Jimmy
  • Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Hellmann, Klaus
  • Klifovet GmbH, Munich, Germany.
Braun, Gabriele
  • Klifovet GmbH, Munich, Germany.
Beerts, Charlotte
  • Boehringer Ingelheim Veterinary Medicine Belgium, Evergem, Belgium.
  • Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Spaas, Jan H
  • Boehringer Ingelheim Veterinary Medicine Belgium, Evergem, Belgium.
  • Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

Grant Funding

  • HBC.2020.2227 / Agentschap Innoveren en Ondernemen

References

This article includes 26 references
  1. Murray RC, Dyson SJ, Tranquille C, Adams V. Association of type of sport and performance level with anatomical site of orthopaedic injury diagnosis.. Equine Vet J 2006;38(36):411-416.
  2. Williams RB, Harkins LS, Hammond CJ, Wood JLN. Racehorse injuries, clinical problems and fatalities recorded on British racecourses from flat racing and National Hunt racing during 1996, 1997 and 1998.. Equine Vet J 2001;33(5):478-486.
  3. Sloet Van Oldruitenborgh-Oosterbaan MM, Genzel W, van Weeren PR. A pilot study on factors influencing the career of Dutch sport horses.. Equine Vet J 2010;42(38):28-32.
  4. Dowling BA, Dart AJ, Hodgson DR, Smith RKW. Superficial digital flexor tendonitis in the horse.. Equine Vet J 2000;32(5):369-378.
  5. Spaas JH, Guest DJ, Van de Walle GR. Tendon regeneration in human and equine athletes: Ubi Sumus-quo Vadimus (where are we and where are we going to)?. Sports Med 2012;42(10):871-890.
  6. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RKW. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.. Equine Vet J 2012;44(1):25-32.
  7. del Bue M, Riccò S, Ramoni R, Conti V, Gnudi G, Grolli S. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo.. Vet Res Commun 2008;32(Suppl 1):S51-S52.
  8. Beerts C, Suls M, Broeckx SY, Seys B, Vandenberghe A, Declercq J. Tenogenically induced allogeneic peripheral blood mesenchymal stem cells in allogeneic platelet-rich plasma: 2-year follow-up after tendon or ligament treatment in horses.. Front Vet Sci 2017;4:158.
  9. Burk J, Wittenberg-Voges L, Brehm W, Schubert S, Geburek F. Mesenchymal stromal cells for treatment of tendon injuries: first insights from a controlled, randomized, blinded veterinary patient study.. 9th conference of the German Stem Cell Network (GSCN) 2021.
  10. Smith RKW, Werling NJ, Dakin SG, Alam R, Goodship AE, Dudhia J. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy.. PloS One 2013;8(9):e75697.
  11. Gillis CL. Rehabilitation of tendon and ligament injuries.. Proc Am Assoc Equine Pract 1997;43:306-309.
  12. Broeckx S. Tenogenesis of equine peripheral blood-derived mesenchymal stem cells: in vitro versus in vivo.. J Tissue Sci Eng 2012;S11:1-6.
  13. Spaas JH, de Schauwer C, Cornillie P, Meyer E, van Soom A, de Walle GR. Culture and characterisation of equine peripheral blood mesenchymal stromal cells.. Vet J 2013;195(1):107-113.
  14. Depuydt E, Broeckx SY, van Hecke L, Chiers K, van Brantegem L, van Schie H. The evaluation of equine allogeneic tenogenic primed mesenchymal stem cells in a surgically induced superficial digital flexor tendon lesion model.. Front Vet Sci 2021;8:641441.
  15. Rantanen NW, Jorgensen JS, Genovese RL. Ultrasonographic evaluation of the equine limb: technique.. In: Ross MW, Dyson SJ, editors. Diagnosis and management of lameness in the horse. 2nd ed. St. Louis, MO: Saunders; 2011. p. 182-205.
  16. Berglund AK, Fortier LA, Antczak DF, Schnabel L. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.. Stem Cell Res Ther 2017;8(1):288.
  17. Ursini TL, Amelse LL, Elkhenany HA, Odoi A, Carter-Arnold JL, Adair HS. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.. Equine Vet J 2019;51(2):198-205.
  18. Muttini A, Russo V, Rossi E, Mattioli M, Barboni B, Tosi U. Pilot experimental study on amniotic epithelial mesenchymal cell transplantation in natural occurring tendinopathy in horses. Ultrasonographic and histological comparison.. Muscles Ligaments Tendons J 2015;5(1):5-11.
  19. Ricco S, Renzi S, del Bue M, Conti V, Merli E, Ramoni R. Allogeneic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe and effective in the therapy of superficial digital flexor tendonitis in the horse.. Int J Immunopathol Pharmacol 2013;26(1):61-68.
  20. Pacini S, Spinabella S, Trombi L, Fazzi R, Galimberti S, Dini F. Suspension of bone marrow-derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses.. Tissue Eng 2007;13(12):2949-2955.
  21. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?. Bone Marrow Transplant 2003;31(10):861-864.
  22. Winkler T, Von Roth P, Matziolis G, Mehta M, Perka C, Duda GN. Dose-response relationship of mesenchymal stem cell transplantation and functional regeneration after severe skeletal muscle injury in rats.. Tissue Eng Part A 2009;15(3):487-492.
  23. Dyson SJ. Medical management of superficial digital flexor tendonitis: a comparative study in 219 horses (1992-2000).. Equine Vet J 2004;36(5):415-419.
  24. Gibson KT, Burbidge HM, Pfeiffer DU. Superficial digital flexor tendonitis in thoroughbred race horses: outcome following non-surgical treatment and superior check desmotomy.. Aust Vet J 1997;75(9):631-635.
  25. O'Sullivan CB. Injuries of the flexor tendons: focus on the superficial digital flexor tendon.. Clin Tech Equine Pract 2007;6:189-197.
  26. Müller-Quirin J, Dittmann MT, Roepstorff C, Arpagaus S, Latif SN, Weishaupt MA. Riding soundness-comparison of subjective with objective lameness assessments of owner-sound horses at trot on a treadmill.. J Equine Vet 2020;95:103314.

Citations

This article has been cited 0 times.